Vygenerované: 06.07.2026 19:19:27
Súhrn: TOPLINE Swelling in the wrist and second and third metacarpophalangeal (MCP) joints resolved more slowly than that in other joints among patients with rheumatoid arthritis (RA) receiving biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), regardless of the treatment class used METHODOLOGY - Researchers conducted a longitudinal observational study using data from a Swiss registry to determine whether treatment response differed by the location of joints in patients with RA initiating b/tsDMARDs 8 years; 71% women) who had not received any biologic therapy previously and had at least one swollen joint at the initiation of their first TNF inhibitor.
Doplnenie: 8 years; 71% women) who had not received any biologic therapy previously and had at least one swollen joint at the initiation of their first TNF inhibitor.
Súhrn: MANCHESTER, England — The current process for managing psoriasis is like climbing a staircase: “slow, laborious, takes a long time to get onto the right treatment if at all, and you've lost time; the patients are not going to do so well,” Chris Griffiths, MBBS, MD, told participants here at the British Association of Dermatologists 2026 Annual Meeting ” Dermatologists, he explained, need to get patients onto the right care holistically and pharmacologically as early as possible to maintain good control of the disease long-term ” Medicine, he said, is moving from being reactive to proactive, with the P4 medicine model — based on the four-pillar approach of predictive, preventive, personalised, and participatory healthcare — becoming the goal.
Doplnenie: He added that much progress has been made in the understanding of psoriasis over the past two to three decades, but more remains to be done “because we need to be ambitious on behalf of our patients.